Skip to Main Content
Contribute Try STAT+ Today

It’s still early days for efforts to develop gene therapies against hemophilia, but a handful of patients treated with these one-time, potentially curative treatments have now been followed long enough to start measuring clinically relevant outcomes like reductions in bleeding episodes. That’s what matters most to hemophilia patients (and it’s what will form the basis of regulatory approvals), so it’s more significant than looking at surrogate markers of activity such as increases in the activity level of clotting factors.

On Tuesday, Biomarin announced plans to start a phase 3 study in the fourth quarter of its gene therapy BMN 270 for hemophilia A. The biotech company is moving forward with the high dose of BMN 270, which some will see as a controversial decision because Factor VIII activity levels exceeded normal limits in some patients treated in the phase 1-2 study.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.